|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FSIP2 |
Gene summary for FSIP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FSIP2 | Gene ID | 401024 |
| Gene name | fibrous sheath interacting protein 2 | |
| Gene Alias | SPGF34 | |
| Cytomap | 2q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q5CZC0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 401024 | FSIP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.93e-02 | 7.74e-02 | 0.0155 |
| 401024 | FSIP2 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.63e-05 | 5.39e-01 | -0.1088 |
| 401024 | FSIP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.40e-09 | 4.97e-01 | 0.0674 |
| 401024 | FSIP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.98e-04 | 3.12e-01 | 0.294 |
| 401024 | FSIP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.67e-05 | 6.67e-01 | 0.281 |
| 401024 | FSIP2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.76e-02 | 3.74e-01 | 0.3859 |
| 401024 | FSIP2 | CRC-3-11773 | Human | Colorectum | CRC | 9.36e-06 | -2.06e-01 | 0.2564 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FSIP2 | SNV | Missense_Mutation | novel | c.18266A>G | p.Tyr6089Cys | p.Y6089C | Q5CZC0 | protein_coding | probably_damaging(0.996) | TCGA-85-8481-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FSIP2 | SNV | Missense_Mutation | novel | c.20696N>T | p.Ser6899Phe | p.S6899F | Q5CZC0 | protein_coding | probably_damaging(0.999) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FSIP2 | SNV | Missense_Mutation | c.18423N>A | p.His6141Gln | p.H6141Q | Q5CZC0 | protein_coding | probably_damaging(0.921) | TCGA-90-A59Q-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
| FSIP2 | SNV | Missense_Mutation | novel | c.20270N>A | p.Pro6757Gln | p.P6757Q | Q5CZC0 | protein_coding | benign(0.038) | TCGA-90-A59Q-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| FSIP2 | SNV | Missense_Mutation | novel | c.19087C>A | p.Pro6363Thr | p.P6363T | Q5CZC0 | protein_coding | probably_damaging(0.917) | TCGA-96-A4JK-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | CR | |
| FSIP2 | SNV | Missense_Mutation | novel | c.20174C>A | p.Ala6725Glu | p.A6725E | Q5CZC0 | protein_coding | benign(0.018) | TCGA-96-A4JK-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | CR | |
| FSIP2 | SNV | Missense_Mutation | novel | c.19165N>A | p.Val6389Ile | p.V6389I | Q5CZC0 | protein_coding | probably_damaging(0.963) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD | |
| FSIP2 | insertion | Nonsense_Mutation | novel | c.17448_17449insTGAGGAG | p.Asp5817Ter | p.D5817* | Q5CZC0 | protein_coding | TCGA-55-A4DG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| FSIP2 | deletion | Frame_Shift_Del | novel | c.19475delN | p.Gln6493LysfsTer7 | p.Q6493Kfs*7 | Q5CZC0 | protein_coding | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FSIP2 | insertion | Frame_Shift_Ins | novel | c.16824_16825insA | p.Lys5611GlufsTer3 | p.K5611Efs*3 | Q5CZC0 | protein_coding | TCGA-22-5472-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |